These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 17353569

  • 1. Deferasirox.
    Stumpf JL.
    Am J Health Syst Pharm; 2007 Mar 15; 64(6):606-16. PubMed ID: 17353569
    [Abstract] [Full Text] [Related]

  • 2. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G, Frankewich R, Chakraborti T, Choudary J, Al-Fayoumi S, Kacuba A, Castillo S, Robie-Suh K, Rieves D, Weiss K, Pazdur R.
    Oncology (Williston Park); 2006 Dec 15; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [Abstract] [Full Text] [Related]

  • 3. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Cappellini MD, Taher A.
    Expert Opin Pharmacother; 2008 Sep 15; 9(13):2391-402. PubMed ID: 18710363
    [Abstract] [Full Text] [Related]

  • 4. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 5. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 6. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD007477. PubMed ID: 20687088
    [Abstract] [Full Text] [Related]

  • 7. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T, Deferasirox in Sickle Cell Investigators.
    Br J Haematol; 2007 Feb 04; 136(3):501-8. PubMed ID: 17233848
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT, Olin BR.
    Clin Ther; 2007 Oct 04; 29(10):2154-66. PubMed ID: 18042472
    [Abstract] [Full Text] [Related]

  • 9. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Yang LP, Keam SJ, Keating GM.
    Drugs; 2007 Oct 04; 67(15):2211-30. PubMed ID: 17927285
    [Abstract] [Full Text] [Related]

  • 10. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF.
    Acta Haematol; 2008 Oct 04; 119(3):133-41. PubMed ID: 18408362
    [Abstract] [Full Text] [Related]

  • 11. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 12. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE, Hagemann TM.
    Ann Pharmacother; 2006 Jun 21; 40(6):1110-7. PubMed ID: 16735647
    [Abstract] [Full Text] [Related]

  • 13. Clinical application of deferasirox: practical patient management.
    Vichinsky E.
    Am J Hematol; 2008 May 21; 83(5):398-402. PubMed ID: 18058997
    [Abstract] [Full Text] [Related]

  • 14. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P, Marsella M.
    Drug Des Devel Ther; 2015 May 21; 9():6475-82. PubMed ID: 26719673
    [Abstract] [Full Text] [Related]

  • 15. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.
    Health Technol Assess; 2009 Jan 21; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [Abstract] [Full Text] [Related]

  • 16. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ.
    Blood; 2006 May 01; 107(9):3436-41. PubMed ID: 16627763
    [Abstract] [Full Text] [Related]

  • 17. Deferasirox: oral, once daily iron chelator--an expert opinion.
    Agarwal MB.
    Indian J Pediatr; 2010 Feb 01; 77(2):185-91. PubMed ID: 20178010
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Feb 01; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators.
    Am J Hematol; 2013 Dec 01; 88(12):1068-73. PubMed ID: 23946212
    [Abstract] [Full Text] [Related]

  • 20. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
    Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y, CORDELIA study investigators.
    Blood; 2014 Mar 06; 123(10):1447-54. PubMed ID: 24385534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.